Perceptive Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Perceptive Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-686,922	Closed	-$90.4M	–	174
2020 Q4	$90.4M	Hold	686,922	–	–	0.97%	28
2020 Q3	$34.7M	Hold	686,922	–	–	0.51%	52
2020 Q2	$30.1M	Hold	686,922	–	–	0.49%	48
2020 Q1	$33.7M	Sell	686,922 -10,602	-2%	-$540K	0.88%	26
2019 Q4	$40M	Buy	697,524 +10,532	+2%	+$521K	0.8%	33
2019 Q3	$24.7M	Hold	686,992	–	–	0.67%	35
2019 Q2	$21.3M	Hold	686,992	–	–	0.49%	47
2019 Q1	$16.1M	Buy	686,992 +70	+0%	+$1.12K	0.45%	44
2018 Q4	$9.45M	Hold	686,922	–	–	0.36%	52
2018 Q3	$6.86M	Hold	686,922	–	–	0.18%	65
2018 Q2	$14M	Buy	+686,922	New	+$14.4M	0.37%	52

Perceptive Advisors's EIDX Position: Q1 2021 in Review

Perceptive Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 686,922 shares — an estimated $90.4M sold.

Perceptive Advisors first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $90.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Perceptive Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Perceptive Advisors sold 686,922 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $90.4M.
Perceptive Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
Perceptive Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $90.4M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.